Le Lézard
Classified in: Transportation, Health, Sports and recreation
Subject: WOM

InMode Announces P1 Offshore Racing Partnership with Female Driver Victoria Rand


IRVINE, Calif., May 8, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is the first aesthetic company to officially partner with P1 Offshore Racing and sponsor the only female driver, Victoria Rand, as part of Class 1. This partnership signifies a historic step forward in motorsports, and reflects InMode's unwavering dedication to championing and empowering women.

Victoria Rand, hailing from Denmark with a lineage deeply rooted in racing, brings an unparalleled passion for speed and competition in traditional motorsports. From her early days in the Junior Dragster class to achieving international acclaim in the Pro Modified Class, Victoria's journey is one of resilience and determination. Now, she sets her sights on conquering the waves, as she takes the helm of the Morpheus8 Offshore Race Team, powered by a 50 foot, 2,200-horsepower boat alongside world champion Johnny Tomlinson.

"At InMode, our technological advancements span over two decades and have continued to break boundaries in aesthetics, and in enabling women to live their most beautiful lives. We believe that when you look and feel your best, you are unstoppable. Victoria Rand and the Morpheus8 Offshore Race Team embody all of these values, aiming to break through boundaries is a true test of spirit and perseverance," says Spero Theodorou, MD, Chief Medical Officer at InMode. "We are thrilled to support a female driver who is a trailblazer and inspiration for women everywhere."

"I am so excited to be partnering with InMode and P1 Offshore Racing," says Rand. "It is an incredible opportunity to not only make waves in the world of racing, but also be able to provide a platform to inspire women to be bold and confident."

About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

About P1 Offshore
20 years of racing, 18 countries, 700 races. P1 Offshore combines high-speed, free-to-watch sport and family entertainment, hundreds of thousands of spectators and millions of television viewers around the world. Class 1 is the premier class of offshore powerboat racing in the world and is one of the most spectacular marine motorsports.

Press Contact:
Behrman Cesa Communications
[email protected]

Investor Contact:
MS-IR LLC
Miri Segal ? Scharia
[email protected]
Tel: 917-607-8654

Photo - https://mma.prnewswire.com/media/2407298/Victoria_Rand.jpg
Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg

SOURCE InMode Ltd.


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: